PharmTech Drug Digest 11.20
News|Articles|November 15, 2017

Pharmaceutical Technology

  • Pharmaceutical Technology-11-15-2017
  • Volume 2017 ebook
  • Issue 2

Using Human Challenge Trials to Develop Flu Vaccines

Challenge trials may increase in coming years as new and improved challenge agents better emulate “natural” disease states.

A human challenge study offers several advantages when testing drugs or vaccinations for infectious diseases, because proof of efficacy can be measured in humans across a defined period of infection as the exact time at which exposure to the infectious agent is known. Usually this knowledge as to when infection takes place is unknown, and therefore it is also undeterminable as to where on the disease cycle the subject is. Sampling events are scheduled to take specimens at critical periods, and symptomology is carefully monitored throughout. 

Download the 

Vaccine Development and Manufacturing 2017 ebook

.

Article Details

Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
November 2017
Pages: 50–54

Citation

When referring to this article, please cite it as A. Wildfire, "Using Human Challenge Trials to Develop Flu Vaccines," Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).

 


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.